British Journal of Cancer

Article	Citations
Investigation of the gut microbiome, bile acid composition and host immunoinflammatory response in a model of azoxymethane-induced colon cancer at discrete timepoints	190
Correction To: Serplulimab, a novel anti-PD-1 antibody, in patients with microsatellite instability-high solid tumours: an open-label, single-arm, multicentre, phase II trial	158
Advancing radiomics from contrast-enhanced mammography in breast cancer	149
Extruded small extracellular vesicles: splinters of circulating tumour cells may promote cancer metastasis?	140
Impact of clonal TP53 mutations with loss of heterozygosity on adjuvant chemotherapy and immunotherapy in gastric cancer	127
Primary tumor sidedness and negative hyperselection to modulate anti-EGFR-based maintenance strategies in patients with RAS wild-type metastatic colorectal cancer: individual patient data pooled analy	125
The EXO1/Polη/Polι axis as a promising target for miR-3163-mediated attenuation of cancer stem-like cells in non-small cell lung carcinoma	122
Randomised, Phase II study of selumetinib, an oral inhibitor of MEK, in combination with cisplatin and gemcitabine chemotherapy for patients with advanced biliary tract cancer	110
Years of life lost due to cancer in the United Kingdom from 1988 to 2017	110
Modulation of autophagy: a Phase II study of vorinostat plus hydroxychloroquine versus regorafenib in chemotherapy-refractory metastatic colorectal cancer (mCRC)	109
Hit it hard: qualitative patient perspectives on the optimisation of immune checkpoint inhibition	106
Correction: Wnt/ERK/CDK4/6 activation in the partial EMT state coordinates mammary cancer stemness with self-renewal and inhibition of differentiation	106
Correction: YY1 targets tubulin polymerisation-promoting protein to inhibit migration, invasion and angiogenesis in pancreatic cancer via p38/MAPK and PI3K/AKT pathways	106
Normal weight obesity, circulating biomarkers and risk of breast cancer: a prospective cohort study and meta-analysis	104
Clinicopathological and molecular characteristics of RSPO fusion-positive colorectal cancer	99
Breast cancer risk prediction with a modified BOADICEA model in Danish women	97
Comprehensive assessment of actionable genomic alterations in primary colorectal carcinoma using targeted next-generation sequencing	92
Assessments of social vulnerability on laryngeal cancer treatment & prognosis in the US	91
PANTHER: AZD8931, inhibitor of EGFR, ERBB2 and ERBB3 signalling, combined with FOLFIRI: a Phase I/II study to determine the importance of schedule and activity in colorectal cancer	90
Hepatitis B virus X protein promotes MAN1B1 expression by enhancing stability of GRP78 via TRIM25 to facilitate hepatocarcinogenesis	89
Fibroblast growth factor signalling influences homologous recombination-mediated DNA damage repair to promote drug resistance in ovarian cancer	89
Extranodal extension in lung adenocarcinoma: pathological insights and its implication as a histological marker of clinical aggressiveness	89
Metastasis-associated fibroblasts in peritoneal surface malignancies	84
Efficacy of FOLFIRI plus cetuximab vs FOLFIRI plus bevacizumab in 1st-line treatment of older patients with RAS wild-type metastatic colorectal cancer: an analysis of the randomised trial FIRE-3	84
Capecitabine combined with immunotherapy as maintenance therapy improves survival in recurrent/metastatic nasopharyngeal carcinoma: a retrospective cohort study	82

Proactive breast cancer risk assessment in primary care: a review based on the principles of screening	79
Fibroblast activation protein-targeted near-infrared photoimmunotherapy depletes immunosuppressive cancer-associated fibroblasts and remodels local tumor immunity	78
Integrated genomic and transcriptomic analysis reveals the activation of PI3K signaling pathway in HPV-independent cervical cancers	78
Neoplasm risk in individuals with neurofibromatosis 1 – a Danish nationwide cohort study with long-term follow-up	78
Mutational spectrum of TP53 gene correlates with nivolumab treatment efficacy in advanced gastric cancer (TP53MUT study)	77
Metabolic adaptations in prostate cancer	76
Targeting mitochondrial oxidative phosphorylation: lessons, advantages, and opportunities	75
DRP1 inhibition-mediated mitochondrial elongation abolishes cancer stemness, enhances glutaminolysis, and drives ferroptosis in oral squamous cell carcinoma	74
Navigating therapeutic strategies: HPV classification in head and neck cancer	73
Surveillance after childhood cancer: are survivors with an increased risk for cardiomyopathy regularly followed-up?	72
A very-hot food and beverage thermal exposure index and esophageal cancer risk in Malawi and Tanzania: findings from the ESCCAPE case–control studies	70
Genomic ALK alterations in primary and relapsed neuroblastoma	69
Identifying optimal first-line treatment for advanced non-small cell lung carcinoma with high PD-L1 expression: a matter of debate	68
Mismatch repair markers in preoperative and operative endometrial cancer samples; expression concordance and prognostic value	67
Identifying health conditions associated with an increased risk of pancreatic ductal adenocarcinoma at medium term in nationwide electronic health records of primary care physicians	67
The prognostic and biology of tumour-infiltrating lymphocytes in the immunotherapy of cancer	65
Identification of increased dedifferentiation along the Prom1+ cancer cells in Müllerian adenosarcoma with sarcomatous overgrowth	65
Hypoxia- and Postirradiation reoxygenation-induced HMHA1/ARHGAP45 expression contributes to cancer cell invasion in a HIF-dependent manner	64
Circulating tumour DNA monitoring and early treatment for relapse: views from patients with early-stage melanoma	64
Risk of subsequent primary oral cancer in a cohort of 69,460 5-year survivors of childhood and adolescent cancer in Europe: the PanCareSurFup study	63
Somatic hits in mismatch repair genes in colorectal cancer among non-seminoma testicular cancer survivors	62
Optimizing adjuvant treatment strategies for non-pancreatic periampullary cancers	62
Evidence into practice: a national cohort study of NICE-recommended oncological drug therapy utilisation among women diagnosed with invasive breast cancer in England	62
eIF3i facilitates NELFCD translation to promote metastasis via regulating EMT and invadopodia	61
EEF1A2 promotes HIF1A mediated breast cancer angiogenesis in normoxia and participates in a positive feedback loop with HIF1A in hypoxia	61
The SRC-family serves as a therapeutic target in triple negative breast cancer with acquired resistance to chemotherapy	61
The HLA ligandome of oropharyngeal squamous cell carcinomas reveals shared tumour-exclusive peptides for semi-personalised vaccination	58
The impact of the first 2 years of the COVID-19 pandemic on breast cancer diagnoses: a population-based study in England	57
Therapeutic impact of BET inhibitor BI 894999 treatment: backtranslation from the clinic	56
Identification of MYCN non-amplified neuroblastoma subgroups points towards molecular signatures for precision prognosis and therapy stratification	56
A systematic review of microbial markers for risk prediction of colorectal neoplasia	55
Implications of obesity and insulin resistance for the treatment of oestrogen receptor-positive breast cancer	55
Neoadjuvant chemotherapy is noninferior to chemoradiotherapy for early-onset locally advanced rectal cancer in the FOWARC trial	55
The Glasgow Microenvironment Score and risk and site of recurrence in TNM I–III colorectal cancer	54
Clinical utility of BRCA and ATM mutation status in circulating tumour DNA for treatment selection in advanced pancreatic cancer	53
A Phase 1B open-label study of gedatolisib (PF-05212384) in combination with other anti-tumour agents for patients with advanced solid tumours and triple-negative breast cancer	53
Emerging nanomedical strategies for direct targeting of pediatric and adult diffuse gliomas	52
Oxaliplatin induces pyroptosis in hepatoma cells and enhances antitumor immunity against hepatocellular carcinoma	51
Randomised phase II trial of weekly ixabepilone ± biweekly bevacizumab for platinum-resistant or refractory ovarian/fallopian tube/primary peritoneal cancer	51
Serum 25-hydroxyvitamin D concentrations and colorectal cancer incidence in adults with type 2 diabetes	51
Protein markers of ovarian cancer and its subtypes: insights from proteome-wide Mendelian randomisation analysis	50
PTBP1 drives c-Myc-dependent gastric cancer progression and stemness	50
Effect of risk-based screening for upper gastrointestinal cancers: a multi-center real-world study	50
Retraction Note: Toll-like receptor 9 agonist IMO cooperates with everolimus in renal cell carcinoma by interfering with tumour growth and angiogenesis	50
SLC7A11-AS1 contributes to prolonged activation of activin A/Smad signaling by suppressing PPM1A myristoylation in pancreatic cancer	49
Multistate models for the natural history of cancer progression	49
A Phase II study of neoadjuvant axitinib for reducing the extent of venous tumour thrombus in clear cell renal cell cancer with venous invasion (NAXIVA)	48
Long-term trends in incidence, characteristics and prognosis of screen-detected and interval cancers in women participating in the Dutch breast cancer screening programme	48
Albendazole inhibits colon cancer progression and therapy resistance by targeting ubiquitin ligase RNF20	47
Editorial Expression of Concern: Decreased levels of baseline and drug-induced tubulin polymerisation are hallmarks of resistance to taxanes in ovarian cancer cells and are associated with epithelial-	46

Relation knowledge distillation 3D-ResNet-based deep learning for breast cancer molecular subtypes prediction on ultrasound videos: a multicenter study	46
Clinical outcome and prognostic factors for Asian patients in Phase I clinical trials	46
Contralateral breast cancer after radiotherapy and hormone therapy in two cohorts of US breast cancer survivors	45
A comprehensive appraisal of HER2 heterogeneity in HER2-amplified and HER2-low colorectal cancer	44
Adolescent dietary patterns in relation to later prostate cancer risk and mortality in the NIH-AARP Diet and Health Study	44
Long-term use of antihypertensive medications, hypertension and colorectal cancer risk and mortality: a prospective cohort study	43
Cancer in Costello syndrome: a systematic review and meta-analysis	43
Progress and priorities in reducing the time to cancer diagnosis	43
Prognostic significance of PET/CT and its association with immuno-genomic profiling in oesophageal squamous cell carcinoma treated with immunotherapy plus chemoradiotherapy: results from a phase II st	43
Tissue factor in cancer-associated thromboembolism: possible mechanisms and clinical applications	42
Introduction and impact of routine whole genome sequencing in the diagnosis and management of sarcoma	42
Deep learning analysis of histopathological images predicts immunotherapy prognosis and reveals tumour microenvironment features in non-small cell lung cancer	42
Nutritional status, body composition and chemotherapy dosing in children and young people with cancer: a systematic review by the SIOP nutrition network	42
Prognostic relevance of the neurological symptom burden in brain metastases from breast cancer	42
Correction: Menopausal hormone therapy and breast cancer risk: a population-based cohort study of 1.3 million women in Norway	41
High-throughput precision MRI assessment with integrated stack-ensemble deep learning can enhance the preoperative prediction of prostate cancer Gleason grade	41
Correction: Modelled mortality benefits of multi-cancer early detection screening in England	41
Mass spectrometric insights into the protein composition of human cutaneous neurofibromas: comparison of neurofibromas with the overlying skin	41
DNA repair-dependent immunogenic liabilities in colorectal cancer: opportunities from errors	41
Correction: Targeting oncogenic microRNAs from the miR-371~373 and miR-302/367 clusters in malignant germ cell tumours causes growth inhibition through cell cycle disruption	41
Correction: Differential cellular origins of the extracellular matrix of tumor and normal tissues according to colorectal cancer subtypes	41
The in vitro dynamics of pseudo-vascular network formation	40
A metabolomic analysis of adiposity measures and pre- and postmenopausal breast cancer risk in the Nurses’ Health Studies	40
Oesophageal cancer awareness and anticipated time to help-seeking: results from a population-based survey	40
Cost-effectiveness of one-off upper abdominal CT screening as an add-on to lung cancer screening in England	40
Efficacy and quality of life for FOLFOX/bevacizumab +/− irinotecan in first-line metastatic colorectal cancer—final results of the AIO CHARTA trial	40
Characterisation of FLT3 alterations in childhood acute lymphoblastic leukaemia	39
Measurable residual disease analysis in paediatric acute lymphoblastic leukaemia patients with ABL-class fusions	39
Clinical efficacy and immune response of neoadjuvant camrelizumab plus chemotherapy in resectable locally advanced oesophageal squamous cell carcinoma: a phase 2 trial	38
Capturing breast cancers’ copy-number landscape in routine pathology: Exploiting low-resolution, genome-wide sequencing to identify HRD and beyond	38
Population-based nasopharyngeal carcinoma survival in southern China	38
Manassantin A inhibits tumour growth under hypoxia through the activation of chaperone-mediated autophagy by modulating Hsp90 activity	38
Cancer risk in individuals with polydactyly: a Swedish population-based cohort study	38
A multimodal imaging study to highlight elastin-derived peptide pro-tumoral effect in a pancreatic xenograft model	38
Routes to diagnosis for hepatocellular carcinoma patients: predictors and associations with treatment and mortality	37
Deciphering the central role of TMOD2 in colorectal cancer progression and metastasis	37
What do women think about having received their breast cancer risk as part of a risk-stratified NHS Breast Screening Programme? A qualitative study	37
Hyperglycaemia induces metabolic reprogramming into a glycolytic phenotype and promotes epithelial-mesenchymal transitions via YAP/TAZ-Hedgehog signalling axis in pancreatic cancer	37
Safety, tolerability, and pharmacokinetics of Aurora kinase B inhibitor AZD2811: a phase 1 dose-finding study in patients with advanced solid tumours	37
The mediating role of combined lifestyle factors on the relationship between education and gastric cancer in the Stomach cancer Pooling (StoP) Project	37
Correction to: Methyl-CpG-binding domain 3 inhibits epithelial–mesenchymal transition in pancreatic cancer cells via TGF-β/Smad signalling	37
Benchmarking standard-of-care and emerging genomic approaches to enhance diagnosis in pediatric acute lymphoblastic leukemia	37
Alkaline phosphatase decline and pain response as predictors of overall survival benefit in patients treated with radium-223: a post hoc analysis of the REASSURE study	37
Molecular response assessment using circulating tumor DNA (ctDNA) in advanced solid tumors	36
Transcriptomic and functional analyses reveal a tumour-promoting role for the IL-36 receptor in colon cancer and crosstalk between IL-36 signalling and the IL-17/ IL-23 axis	36
50 years on and still very much alive: ‘Apoptosis: a basic biological phenomenon with wide-ranging implications in tissue kinetics’	36
Immune evasion in lung metastasis of leiomyosarcoma: upregulation of EPCAM inhibits CD8+ T cell infiltration	36
Confidence bands in survival analysis	36
MET exon 14 skipping mutation drives cancer progression and recurrence via activation of SMAD2 signalling	36
Chromatin accessibility uncovers KRAS-driven FOSL2 promoting pancreatic ductal adenocarcinoma progression through up-regulation of CCL28	36
The prognostic value of MEK pathway–associated estrogen receptor signaling activity for female cancers	36
Thinking inside the box: intracellular roles for complement system proteins come into focus	36
Extending the dosing intervals of nivolumab: model-based simulations in unselected cancer patients	36
Germline BRCA1/2 status and chemotherapy response score in high-grade serous ovarian cancer	36
A UK prospective multicentre decision impact, decision conflict and economic evaluation of the 21-gene assay in women with node+ve, hormone receptor+ve, HER2-ve breast cancer	35
Integrated proteomics and scRNA-seq analyses of ovarian cancer reveal molecular subtype-associated cell landscapes and immunotherapy targets	35
The prognostic impact of peritoneal tumour DNA in gastrointestinal and gynaecological malignancies: a systematic review	35
Novel prognostic implications of complement activation in the tumour microenvironment for de novo metastatic BRAF V600E mutant colorectal cancer	35
Circulating tumour DNA and its clinical utility in predicting treatment response or survival in patients with metastatic colorectal cancer: a systematic review and meta-analysis	35
Exploiting dietary fibre and the gut microbiota in pelvic radiotherapy patients	34
Regulatory non-coding somatic mutations as drivers of neuroblastoma	34
Pathological complete response, category change, and prognostic significance of HER2-low breast cancer receiving neoadjuvant treatment: a multicenter analysis of 2489 cases	34
Liquid BIOpsy for MiNimal RESidual DiSease Detection in Head and Neck Squamous Cell Carcinoma (LIONESS)—a personalised circulating tumour DNA analysis in head and neck squamous cell carcinoma	34
Correction to: The Cancer Research UK Stratified Medicine Programme as a model for delivering personalised cancer care	34
Sequential targeting of PARP with carboplatin inhibits primary tumour growth and distant metastasis in triple-negative breast cancer	34
Glycometabolic reprogramming-mediated proangiogenic phenotype enhancement of cancer-associated fibroblasts in oral squamous cell carcinoma: role of PGC-1α/PFKFB3 axis	34
A Phase Ib/II study of IGF-neutralising antibody xentuzumab with enzalutamide in metastatic castration-resistant prostate cancer	34
Identification of diagnostic biomarkers in prostate cancer-related fatigue by construction of predictive models and experimental validation	34
Immune checkpoint inhibitor combinations—current and emerging strategies	34
UK Biobank: a globally important resource for cancer research	34
Cannabinoids induce cell death in leukaemic cells through Parthanatos and PARP-related metabolic disruptions	34
Hypoxia does not predict lack of benefit from adjuvant radiotherapy for patients with early stage breast cancer	33
Trifluridine/tipiracil+bevacizumab (BEV) vs. fluoropyrimidine-irinotecan+BEV as second-line therapy for metastatic colorectal cancer: a randomised noninferiority trial	33
DNA ploidy and PTEN as biomarkers for predicting aggressive disease in prostate cancer patients under active surveillance	33
Recurrent somatic mutations of FAT family cadherins induce an aggressive phenotype and poor prognosis in anaplastic large cell lymphoma	33
Correction: Chromatin profile-based identification of a novel ER-positive breast cancer subgroup with reduced ER-responsive element accessibility	33
Reply to Dr. Rafael Rosell: Shedding some light on the unresolved issue of YAP1 Ser397 phosphorylation in cancer	33
VIVA1: a more invasive subclone of MDA-MB-134VI invasive lobular carcinoma cells with increased metastatic potential in xenograft models	33
Postdiagnosis physical activity is associated with improved survival in prostate cancer patients treated with surgery but not with radiation therapy	32
A systematic review and meta-analysis of toxicity and treatment outcomes with pharmacogenetic-guided dosing compared to standard of care BSA-based fluoropyrimidine dosing	32

Plasma extracellular vesicle circRNA signature and resistance to abiraterone in metastatic castration-resistant prostate cancer	32
Stroma AReactive Invasion Front Areas (SARIFA) and the tumour immune microenvironment in colorectal cancer	32
Preferences for multi-cancer tests (MCTs) in primary care: discrete choice experiments of general practitioners and the general public in England	32
Comprehensive multiplexed immune profiling of the ductal carcinoma in situ immune microenvironment regarding subsequent ipsilateral invasive breast cancer risk	32
Imipridones inhibit tumor growth and improve survival in an orthotopic liver metastasis mouse model of human uveal melanoma	32
Galectin-9-driven immunosuppressive macrophage population shapes the lymph node metastatic microenvironment	31
Outcomes of patients with HER2-negative metastatic breast cancer after platinum- and non-platinum-based first-line chemotherapy among patients with and without pathogenic germline BRCA1/2 mutations	31
The role of genetic predisposition in cardiovascular risk after cancer diagnosis: a matched cohort study of the UK Biobank	31
Reasons for non-feasibility of therapeutic drug monitoring of oral targeted therapies in oncology – an analysis of the closed cohorts of a multicentre prospective study	31
Impact of obesity on chemotherapy dosing of carboplatin and survival of women with ovarian cancer	31
EIF4A3-negatively driven circular RNA β-catenin (circβ-catenin) promotes colorectal cancer progression via miR-197-3p/CTNND1 regulatory axis	31
HECTD3 regulates the tumourigenesis of glioblastoma by polyubiquitinating PARP1 and activating EGFR signalling pathway	31
Single-cell sequencing of PIT1-positive pituitary adenoma highlights the pro-tumour microenvironment mediated by IFN-γ-induced tumour-associated fibroblasts remodelling	30
Survival outcomes of ERBB2-amplified metastatic colorectal cancer treated with first-line chemotherapy	30
Targeting oncogenic microRNAs from the miR-371~373 and miR-302/367 clusters in malignant germ cell tumours causes growth inhibition through cell cycle disruption	30
Overall survival with maintenance olaparib in platinum-sensitive relapsed ovarian cancer by somatic or germline BRCA and homologous recombination repair mutation status	30
Breast cancer hypoxia in relation to prognosis and benefit from radiotherapy after breast-conserving surgery in a large, randomised trial with long-term follow-up	30
Breast cancer cell-derived adrenomedullin confers cancer-associated adipose remodeling through the cAMP/Creb1/Zeb1 axis	30
Sorafenib plus selective internal radiotherapy with 90Y resin microspheres for the treatment of uveal melanoma with liver metastasis: a phase I trial	30
Resectability, conversion, metastasectomy and outcome according to RAS and BRAF status for metastatic colorectal cancer in the prospective RAXO study	30
Health benefits and harms of mammography screening in older women (75+ years)—a systematic review	29
Non-muscle-invasive micropapillary bladder cancer has a distinct lncRNA profile associated with unfavorable prognosis	29
Repositioning canakinumab for non-small cell lung cancer—important lessons for drug repurposing in oncology	29
MicroRNAs as biomarkers for prostate cancer prognosis: a systematic review and a systematic reanalysis of public data	29
Sodium nitrite orchestrates macrophage mimicry of tongue squamous carcinoma cells to drive lymphatic metastasis	29
Prognostic significance of pathogenic variants in BRCA1, BRCA2, ATM and PALB2 genes in men undergoing hormonal therapy for advanced prostate cancer	29
Impact of the selective A2AR and A2BR dual antagonist AB928/etrumadenant on CAR T cell function	29
Response to: Genetic risk scores may compound rather than solve the issue of prostate cancer overdiagnosis (BJC-LT3342090)	28
Cancer-associated fibroblasts expressing fibroblast activation protein and podoplanin in non-small cell lung cancer predict poor clinical outcome	28
Exosomal transfer of miR-181b-5p confers senescence-mediated doxorubicin resistance via modulating BCLAF1 in breast cancer	28
The National COVID Cancer Antibody Survey: a hyper-accelerated study proof of principle for cancer research	28
COLUMBIA-1: a randomised study of durvalumab plus oleclumab in combination with chemotherapy and bevacizumab in metastatic microsatellite-stable colorectal cancer	28
Editorial Expression of Concern: Extracellular, cell-permeable survivin inhibits apoptosis while promoting proliferative and metastatic potential	28
Nonrandomised controlled trial in recurrent glioblastoma patients: the promise of autologous tumour lysate-loaded dendritic cell vaccination	28
Comparison of methods for cancer stem cell detection in prognosis of early stages NSCLC	27
Obituary – Margaret Wilcox	27
Role of 18F-FDG-PET/CT in the initial staging of very high-risk Ewing Sarcoma in a prospective multicentric Phase II Study: Is there still a place for bone marrow sampling?	27
Natural immunity to SARS-CoV-2 and breakthrough infections in vaccinated and unvaccinated patients with cancer	27
Experimental Cancer Medicine Centre (ECMC) network proposal for a consensus gene panel for pan-cancer sequencing: a Delphi methodology	27
ctDNA variations according to treatment intensity in first-line metastatic colorectal cancer	27
Correction: DKC1 enhances angiogenesis by promoting HIF-1α transcription and facilitates metastasis in colorectal cancer	26
Inhibition of the AURKA/YAP1 axis is a promising therapeutic option for overcoming cetuximab resistance in colorectal cancer stem cells	26
Ovarian cancer pathology characteristics as predictors of variant pathogenicity in BRCA1 and BRCA2	26
Dynamic nature of BRAF or KRAS p.G12C mutations in second-line therapy for advanced colorectal cancer patients: do early and late effects exist?	26
Modelled mortality benefits of multi-cancer early detection screening in England	26
Hypoxia-inducible factor 3α1 increases epithelial-to-mesenchymal transition and iron uptake to drive colorectal cancer liver metastasis	26
A study of subjective memory impairment in long-term testicular cancer survivors	25
Targeting the untargetable: RB1-deficient tumours are vulnerable to Skp2 ubiquitin ligase inhibition	25
Anti-angiogenic therapy using the multi-tyrosine kinase inhibitor Regorafenib enhances tumor progression in a transgenic mouse model of ß-cell carcinogenesis	25
A combination of intrinsic and extrinsic features improves prognostic prediction in malignant pleural mesothelioma	25
Understanding genetic architecture of breast cancer: how can proteome-wide association studies contribute?	25
AKT/mTOR as a targetable hub to overcome multimodal resistance to EGFR inhibitors in oesophageal squamous cell carcinoma	25
The long noncoding RNA lncZBTB10 facilitates AR function via S-palmitoylation to promote prostate cancer progression and abiraterone resistance	25
Mutation of the proline P81 into a serine modifies the tumour suppressor function of the von Hippel–Lindau gene in the ccRCC	25
Risk-reducing mastectomy and breast cancer mortality in women with a BRCA1 or BRCA2 pathogenic variant: an international analysis	24
Associations between serum glucose, insulin, insulin resistance and the risk of incident primary liver cancer or chronic liver disease mortality: a nested case–control study	24
Tumour-based epigenetic signatures as markers of prostate cancer aggressiveness after radical prostatectomy	24
Multicentric validation of diagnostic tests based on BC-116 and BC-106 urine peptide biomarkers for bladder cancer in two prospective cohorts of patients	24
UDP-glucose ceramide glucosyltransferase promotes radioresistance via membrane reorganization to maintain redox balance in glioblastoma	24
Attention-based deep learning for breast lesions classification on contrast enhanced spectral mammography: a multicentre study	24
The emergence of RAS mutations in patients with RAS wild-type mCRC receiving cetuximab as first-line treatment: a noninterventional, uncontrolled multicenter study	24
Epithelial−mesenchymal transition induced by tumor cell-intrinsic PD-L1 signaling predicts a poor response to immune checkpoint inhibitors in PD-L1-high lung cancer	24
Tumour microenvironment characterisation to stratify patients for hyperthermic intraperitoneal chemotherapy in high-grade serous ovarian cancer (OVHIPEC-1)	24
Prognostic relevance of HRDness gene expression signature in ovarian high-grade serous carcinoma; JGOG3025-TR2 study	24
Targeting serine/glycine metabolism improves radiotherapy response in non-small cell lung cancer	24
Intratumour heterogeneity, from hypothesis to the clinic	24
Regulatory T cells induce a suppressive immune milieu and promote lymph node metastasis in intrahepatic cholangiocarcinoma	24
Genome-wide polygenic risk scores for colorectal cancer have implications for risk-based screening	24
Platelets induce CD39 expression in tumor cells to facilitate tumor metastasis	24
Interventional pharmacoeconomics for immune checkpoint inhibitors through alternative dosing strategies	24
Prognostic value of post-operative iron biomarkers in colorectal cancer: population-based patient cohort	24
The Rac1-USP11 feedback amplification loop: a radiation-activated engine driving radioresistance in hepatocellular carcinoma	24
Hormone replacement therapy and cancer mortality in women with 17 site-specific cancers: a cohort study using linked medical records	24
Angiogenin and plexin-B2 axis promotes glioblastoma progression by enhancing invasion, vascular association, proliferation and survival	24
Unlocking hidden potential: advancements, approaches, and obstacles in repurposing drugs for cancer therapy	24
Comment on: “Neoadjuvant chemotherapy is noninferior to chemoradiotherapy for early-onset locally advanced rectal cancer in the FOWARC trial”	24
Artificial intelligence-driven microRNA signature for early detection of gastric cancer: discovery and clinical functional exploration	24
Birthweight, height, and body mass index in relation to the expression of stem cell markers among women with benign breast biopsies in the Nurses’ Health Study II	23
Synergistic induction of tertiary lymphoid structures by chemoimmunotherapy in bladder cancer	23
Benzaldehyde suppresses epithelial-mesenchymal plasticity and overcomes treatment resistance in cancer by targeting the interaction of 14-3-3ζ with H3S28ph	23
Correction: TIGIT antibody with PVR competitive ability enhances cancer immunotherapy and capable of eliciting anti-tumour immune memory	23
Correction: E2F7−EZH2 axis regulates PTEN/AKT/mTOR signalling and glioblastoma progression	23
A liquid biopsy signature for predicting early recurrence in patients with gastric cancer	23
Peripheral blood neutrophils contribute to Claudin18.2-specific CAR-T cell treatment resistance in advanced gastric cancer	23
HeLa cells cross-contaminated nasopharyngeal carcinoma cell lines: Still a common problem	23
Anthropometric traits and risk of multiple myeloma: differences by race, sex and diagnostic clinical features	23
Modeling response to the KRAS-G12C inhibitor AZD4625 in KRASG12C NSCLC patient-derived xenografts reveals insights into primary resistance mechanisms	23
Proactive monitoring of drug–drug interactions between direct oral anticoagulants and small-molecule inhibitors in patients with non-small cell lung cancer	23
Editorial Expression of Concern: Upregulation of p27 and its inhibition of CDK2/cyclin E activity following DNA damage by a novel platinum agent are dependent on the expression of p21	23
LHX2 facilitates the progression of nasopharyngeal carcinoma via activation of the FGF1/FGFR axis	22
Semi-mechanistic efficacy model for PARP + ATR inhibitors—application to rucaparib and talazoparib in combination with gartisertib in breast cancer PDXs	22
β-blockers and breast cancer survival by molecular subtypes: a population-based cohort study and meta-analysis	22
Evolving roles of CD38 metabolism in solid tumour microenvironment	22
Adherence to the World Cancer Research Fund/American Institute for Cancer Research cancer prevention recommendations throughout the life course and risk of colorectal cancer precursors	22
Breast cancer metastasis progression is associated with elevated activity of kynurenine monooxygenase and kynureninase	22